Studies have shown that inadequate sleep, especially a lack of deep, restorative sleep (NREM), can significantly slow down ...

Are the reviews authentic, or just clever marketing? While many users report impressive results, there are also mixed ...

A major turning point came when a clinical review in the Journal of Urology and Men’s Health highlighted the effectiveness of ...

The Human Cell Atlas, developed by an international consortium of cytologists, molecular biologists, and data scientists, ...

Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene ...

The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The ...

In addition to the presentations, Viral Kansara, PhD, Vice President, Preclinical Development moderated an ARVO session entitled “Retina/RPE: New drugs, mechanisms of action, and toxicity” and Dr.

AMSTERDAM, the Netherlands, May 09, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today reported financial results for its first fiscal quarter ended March 31, 2025. Key financial results are presented below in ...

Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million, adjusted non-GAAP EBITDA of $195.0 million to $205.0 million, and adjusted non-GAAP diluted earnings per share ...

BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data ...